|
|
BACK
to Summer 2001 HOPE Newsletter Contents
In The News
In The
News
I n 1997, a partnership began between the Stehlin Foundation
and SuperGen, a pharmaceutical company, concerning additional
research and
clinical trials for 9-NC as a treatment for pancreatic cancer.
The last stage of the trials have closed, and as data is compiled
throughout this year, 9-NC takes another huge step towards
becoming a prescribable drug in the public marketplace …
both in America and abroad.
(Clockwise
from bottom left) Dr. John S. Stehlin, Jr., founder, Bobby
Anderson, executive director, Kim Wheless, chairman of the
board of directors, and Dr. Joseph Rubinfeld, president and
chairman of Supergen.
BACK
to Summer 2001 HOPE Newsletter Contents
|
